Chiu T H, Rosenberg H C
Mol Pharmacol. 1983 Mar;23(2):289-94.
The binding kinetics of [3H]Ro 15-1788, a selective benzodiazepine receptor antagonist, to synaptosomal membranes of rat cerebral cortices was studied. [3H]Ro 15-1788 binds with high affinity (dissociation constant, 0.53 nM) to a single class of binding sites (maximal binding capacity, 1.97 pmoles/mg of protein). Equilibrium binding was not affected by gamma-aminobutyric acid (GABA), NaCl, pentobarbital, or pretreatment of the membranes at 37 degrees. Association at 0 degrees was identical whether measured in the absence or presence of GABA or bicuculline methiodide or after preincubation of the membranes at 37 degrees. The association rate under pseudo-first order conditions was curvilinear and consisted of a fast component and a slow component. Dissociation at 0 degrees with 1 X 10(-5)M clonazepam was also curvilinear and could best be fitted by two linear exponential components. The dissociation rate was not altered by GABA, NaCl, pentobarbital, or pretreatment of membranes at 37 degrees. The dissociation rate was similar for 0.1, 1, and 10 nM [3H]Ro 15-1788. The ratio of slow to fast dissociation component for 10 nM [3H]Ro 15-1788 was larger than that for 0.1 and 1 nM [3H]Ro 15-1788. In contrast, the dissociation rate for 20 nM [3H]flunitrazepam ( [3H]FNP) was much greater than that for 2 nM [3H]FNP. Using ligand concentrations occupying the same fraction of receptors, the ratio of slow to fast dissociation components was invariably greater for [3H]Ro 15-1788 than that for [3H]FNP. The rate of dissociation for [3H]Ro 15-1788 was faster under pre-equilibrium conditions than under equilibrium conditions. These results, discussed in terms of the cyclic model of interaction between receptors and benzodiazepines, suggest that [3H]Ro 15-1788 is a powerful ligand in inducing conformational changes in the initial, more labile, binary complex. They also suggest that different conformational states deduced from studies of in vitro binding kinetics may not correspond to the distinct pharmacological actions of benzodiazepines. It is speculated that intrinsic activities of benzodiazepines probably are determined by the step beyond the complex formation and conformational changes suggested to occur by these studies of binding kinetics.
研究了选择性苯二氮䓬受体拮抗剂[3H]Ro 15 - 1788与大鼠大脑皮质突触体膜的结合动力学。[3H]Ro 15 - 1788以高亲和力(解离常数为0.53 nM)与单一类别的结合位点结合(最大结合容量为1.97 pmoles/mg蛋白质)。平衡结合不受γ-氨基丁酸(GABA)、氯化钠、戊巴比妥或在37℃对膜进行预处理的影响。在0℃时,无论在不存在或存在GABA或甲碘化荷包牡丹碱的情况下测量,还是在膜于37℃预温育后测量,结合速率均相同。在伪一级条件下的结合速率呈曲线状,由一个快速成分和一个缓慢成分组成。在0℃用1×10(-5)M氯硝西泮解离也呈曲线状,最好用两个线性指数成分拟合。解离速率不受GABA、氯化钠、戊巴比妥或在37℃对膜进行预处理的影响。对于0.1、1和10 nM的[3H]Ro 15 - 1788,解离速率相似。10 nM[3H]Ro 15 - 1788的缓慢解离成分与快速解离成分的比率大于0.1和1 nM[3H]Ro 15 - 1788的该比率。相比之下,20 nM[3H]氟硝西泮([3H]FNP)的解离速率远大于2 nM[3H]FNP的解离速率。使用占据相同受体分数的配体浓度时,[3H]Ro 15 - 1788的缓慢解离成分与快速解离成分的比率始终大于[3H]FNP的该比率。在预平衡条件下,[3H]Ro 15 - 1788的解离速率比平衡条件下更快。根据受体与苯二氮䓬相互作用的循环模型讨论这些结果,表明[3H]Ro 15 - 1788是诱导初始的、更不稳定的二元复合物构象变化的强效配体。它们还表明,从体外结合动力学研究推断出的不同构象状态可能与苯二氮䓬的不同药理作用不对应。据推测,苯二氮䓬的内在活性可能由这些结合动力学研究表明发生的复合物形成和构象变化之后的步骤决定。